Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promethera Bio, EMD Millipore to Develop a Liver Pharmaco-Toxicological Assay

Published: Tuesday, March 11, 2014
Last Updated: Tuesday, March 11, 2014
Bookmark and Share
Companies collaborate to develop an improved ready-to-use microfluidic perfusion liver assay.

This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism. Early availability of reliable human liver-based assays is critical to the pharmaceutical industry when deciding to bring a lead compound in clinical phase development. 

With their combined expertise and synergies, the companies are well positioned to develop a ready-to-use long-term liver-based assay. The Promethera Biosciences team is specialized in isolating, expanding and characterizing human liver progenitor cells for both cell therapy and liver cell based assays. EMD Millipore is a global life science company with an extensive portfolio of cell analysis instruments, research reagents and assays, cell culture and sample preparation products, plus advanced microfluidic cell culture as well as drug discovery services. 

Promethera Biosciences has identified a novel adult human hepatic progenitor cell population that can be maintained in vitro in two-dimensional and three-dimensional cell culture conditions providing new models for testing in vitro drug metabolism: Promethera H2Screen and H3screen. This technology is the object of a patent application filed by Promethera Biosciences. There are various benefits with this new technology; Promethera Biosciences cell-based models are derived from healthy human livers and acquire a metabolic capacity within the range of primary hepatocytes. They have long-term stability in culture as well as potential for large-scale production and reproducibility across batches. 

EMD Millipore’s ‘Pearl’ microfluidic technology maintains hepatocyte functionality by mimicking the liver microenvironment. When liver cells are cultured in the ‘Pearl’ format they recover key metabolic functions and could display phenotypic profiles of the intact organ for over a month. 

The project for developing a new product combining the strengths of EMD Millipore 'Pearl' microfluidic technology and of Promethera Biosciences H2Screen/H3Screen cells has been selected by the Belgian Walloon Region Biocluster (BioWin) and the Massachusetts Life Sciences Center (MLSC). It will be funded 900K€ in total for both partners. 

The Belgian Walloon region and the Massachusetts Life Sciences Center (MLSC) are partners in the International Collaborative Industry Program (ICIP). The program’s objective is to promote and motivate collaboration between life sciences companies in Massachusetts (USA) and other countries by facilitating partnerships, supporting exciting new projects, and providing joint funding for helping to swiftly design and develop innovative products and services. 

In April 2013 a call was launched with four partner foreign regions of the Massachusetts Life Sciences Center in the ICIP program. Promethera Biosciences and EMD Millipore were one of the four collaborative projects selected by independent Belgian and American panels of experts. 

”We are very pleased to initiate this collaboration with EMD Millipore and to combine our expertise to develop a ready to use liver based assay. We sincerely thank the Walloon region and the MLSC for funding this innovative project”, said Eric Halioua, Chief Executive Officer of Promethera Biosciences. 

“The opportunity to work closely with Promethera over the course of the project, speaks to the nature of our organization: enabling our partners to conduct potentially life-saving research,” says Robert Yates, President and CEO of EMD Millipore. “We are looking forward to building our relationship and more importantly to the outcomes this partnership has the potential to deliver. A sincere thanks to the MLSC for the opportunity to see what this collaboration can achieve and more importantly the continued support of the Massachusetts Life Sciences industry.” 

An urgent need for reliable human liver-based assays for early preclinical testing 
Early availability of reliable human liver-based assays is critical to the pharmaceutical industry in deciding to bring a lead compound in clinical phase development. 30% of drug candidates fail during clinical development due to toxicity issues. Hepatocyte (liver cells) based studies represent 85% of in vitro toxicology assays. But current models are limited by key technological challenges such as long-term stability of hepatic functionality to allow chronic toxicity testing, and obtaining a stable and consistent human cell source at acceptable cost. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Futuristic Brain Probe Allows for Wireless Control of Neurons
NIH-funded scientists developed an ultra-thin, minimally invasive device for controlling brain cells with drugs and light.
Microfluidic Device Mixes And Matches DNA For Synthetic Biology
Researchers have developed a microfluidic device that quickly builds packages of DNA and delivers them into bacteria or yeast for further testing.
Artificial Pancreas Controls Diabetes
Scientists are reporting the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar, or glucose, level and can automatically release insulin as needed.
Major Step for Implantable Drug-Delivery Device
MIT spinout signs deal to commercialize microchips that release therapeutics inside the body.
Smart Insulin Patch Could Replace Painful Injections for Diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
The Secrets of Secretion
Researchers have hacked nature's blueprints to create a new technology that could have broad-reaching impact on drug delivery systems and self-healing and anti-fouling materials.
New Tool on Horizon for Surgeons Treating Cancer Patients
Surgeons could know while their patients are still on the operating table if a tissue is cancerous, according to researchers.
Heartbeat on a Chip Could Improve Pharmaceutical Tests
A gravity-powered chip that can mimic a human heartbeat outside the body could advance pharmaceutical testing and open new possibilities in cell culture because it can mimic fundamental physical rhythms.
Unravelling the Mysteries of Carbonic Acid
Researchers have shown how gaseous carbon dioxide molecules are solvated by water to initiate the proton transfer chemistry that produces carbonic acid and bicarbonate.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!